Skip to main content

Table 1 Baseline and Descriptive Characteristics

From: A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms

Group

Gas Defense

(n = 30)

Placebo

(n = 31)

Site

  

   Dominican Republic

27 (90%)

27 (87%)

   Miami, FL

3 (10%)

4 (4%)

Age, Years

34.8 ± 12.5

38.2 ± 12.6

Gender

  

   Female

16 (53%)

17 (55%)

   Male

14 (47%)

14 (45%)

Ethnicity

  

   Hispanic

27 (90%)

28 (90%)

   Non-Hispanic

3 (10%)

3 (10%)

Race

  

   Black/AA

8 (27%)

7 (23%)

   Caucasian

9 (30%)

9 (29%)

   Other

12 (43%)

15 (48%)

Height, cm

164.2 ± 8.6

165.8 ± 9.8

Weight, kg

71.4 ± 14.1

79.2 ± 19.3

Status

  

   Completed Protocol

30 (100%)

30 (97%)

   Early Termination

0 (0%)

1 (3%)

Heart Rate, beats/minute

69.9 ± 12.1

70.7 ± 10.3

Systolic Blood Pressure, mm Hg

121.2 ± 17.0

122.2 ± 10.9

Diastolic Blood Pressure, mm Hg

75.1 ± 9.0

76.0 ± 7.2

GSRS - Abdominal Pain Subscore

3.17 ± 1.85

3.14 ± 1.48

GSRS - Abdominal Distension Subscore

3.38 ± 2.13

4.14 ± 1.43

GSRS - Increased Flatus Subscore

3.86 ± 1.92

4.07 ± 1.53

GSRS - Total GI Symptom Score

40.8 ± 19.8

39.4 ± 12.1

SODA - Bloating Subscore

2.52 ± 1.48

2.93 ± 1.25

SODA - Gas Subscore

3.28 ± 0.96

3.28 ± 0.84

SODA - Non-pain Symptoms Score

16.83 ± 3.35

17.00 ± 2.09

SODA - Satisfaction Score

8.3 ± 3.4

9.2 ± 3.5

SF-36v2 - Physical Component Summary

49.9 ± 8.5

49.0 ± 9.9

SF-36v2 - Mental Component Summary

51.3 ± 10.1

51.3 ± 9.9

  1. Values are expressed as mean ± standard deviation.